Esthesioneuroblastoma of the Nasal Cavity. (June 2015)

• Record Type: Journal Article
• Authors: Hollen, Tyler R.; Morris, Christopher G.; Kirwan, Jessica M.; Amdur, Robert J.; Werning, John W.; Vaysberg, Mikhail; Mendenhall, William M.
• Is Part Of: American journal of clinical oncology. Volume 38:Number 3(2015)
• Publication Date: 2015-06
• Subjects: esthesioneuroblastoma -- surgery -- radiation therapy -- nasal cavity -- outcomes; Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0b013e31829b5631
• Languages: English
• ISSNs: 0277-3732

Abstract

Abstract : Objectives: Esthesioneuroblastoma is an uncommon cancer of the nasal cavity. We describe the outcomes for 26 patients treated with curative intent with photon radiotherapy (RT) at the University of Florida. Methods: Between May 1972 and June 2007, 26 patients received RT for previously untreated esthesioneuroblastoma of the nasal cavity. Sixteen patients were males and 10 were females with a median age of 55 years (range, 3 to 82 y). The modified Kadish stage distribution was: B, 7 patients; C, 17 patients; and D, 2 patients. Treatment modalities included the following: definitive RT, 5 patients; preoperative RT, 2 patients; and postoperative RT after resection, 19 patients. Elective neck irradiation (ENI) was performed in 17 (71%) of 24 N0 patients. Results: Rates of local control, cause-specific survival, and absolute overall survival at 5 years were 79%, 72%, and 69%, respectively. Overall survival among patients treated with definitive RT was 20% at 5 years, compared with 81% among those who underwent surgery and adjuvant RT ( P =0.01). One (6%) of 17 patients who received ENI developed a recurrence in the neck and was successfully salvaged. Ultimate neck control was 100% at 5 years for patients who received ENI versus 69% among those not receiving ENI ( P =0.0173). Conclusions: Resection combined with adjuvant RT is more effective than surgery or RT alone in the treatment of esthesioneuroblastoma. ENI reduces the risk of regional relapse in patients with Kadish stage B and C cancers.